Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy to Primary Lesion in Metastatic NSCLC
NCT04776083Phase 3Completed
- Sponsor
- Menoufia University
- Start
- Sep 2020
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Menoufia University. Primary endpoints: progression free survival at 6 months and patients quality of life at 6 months. Started Sep 2020; status: completed.
Beyond the preview
Go deeper on NCT04776083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776083.